AKAN vs BDRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.
Compare Another Pair
Related Comparisons
AKAN vs BDRX: Head-to-Head Comparison
This page compares Akanda Corp. (AKAN) and Biodexa Pharmaceuticals Plc (BDRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.